ABHD4-Regulating RNA Panel: Novel Biomarkers in Acute Coronary Syndrome Diagnosis

Abstract

Background: Acute coronary syndrome (ACS) is a major cause of death all over the world. STEMI represents a type of myocardial infarction with acute ST elevation. We aimed to assess the predictive power of potential RNA panel expression in acute coronary syndrome. Method: We used in silico data analysis to retrieve RNAs related to glycerophospholipid metabolism dysregulation and specific to ACS that results in the selection of Alpha/Beta hydrolase fold domain4 (ABHD4) mRNA and its epigenetic regulators (Foxf1 adjacent noncoding developmental regulatory RNA (FENDRR) lncRNA, miRNA-221, and miRNA-197). We assessed the expression of the serum RNA panel in 68 patients with ACS, 21 patients with chest pain due to non-cardiac causes, and 21 healthy volunteers by quantitative real-time polymerase chain reaction. Results: The study data showed significant down regulation in the expression of the serum levels of FENDRR lncRNA and miRNA-221-3p by 120-fold and 22-fold in Unstable angina (UA) in comparison with healthy volunteers, and by 8.6-fold and 2-fold in ST segment elevation myocardial infarction (STEMI) patients versus UA; concomitant upregulation in the expression of ABHD4 mRNA and miRNA-197-5p by 444-fold and 10-fold in UA compared with healthy volunteers, and by 1.54-fold and 4.5-fold in STEMI versus unstable angina. Performance characteristics analysis showed that the ABHD4-regulating RNA panel were potential biomarkers for prediction of ACS. Moreover, there was a significant association between the 2 miRNAs and ABHD4 mRNA and the regulating FENDRR lncRNA. Conclusion: Collectively, ABHD4 mRNA regulating RNA panel based on putative interactions seems to be novel non-invasive biomarkers that could detect ACS early and stratify severity of the condition that could improve health outcome.

Clinical Study on the Treatment of Acute Coronary Syndrome in Remission with Shexiang Baoxin Pill Combined With Metoprolol Succinate

“…Previous studies have shown that SBP can improve endothelial dysfunction. Since endothelial dysfunction is a key factor in cardiovascular system diseases development, restoring and maintaining endothelial cells normal function has been considered as an effective treatment for ACS [13] . When the coronary arteries stimulated, the endothelial barrier injured, the permeability increased and the accumulation of lipids and leukocytes into the intima accelerated, promoting vascular stenosis, then ischemic heart disease and stroke happened.…”

Targeting Circulating lncRNA ENST00000538705.1 Relieves Acute Coronary Syndrome via Modulating ALOX15

“…Nevertheless, indepth analysis is needed to uncover the pathogenesis of ACS. Although a few thousands of lncRNAs have been functionally characterized in ACS, their potential mechanisms in ACS remain greatly indistinct [25][26][27]. In our study, we adopted microarray technology to obtain the expression data of lncRNAs and mRNAs in serum specimens from 4 patients with ACS and 4 healthy controls.…”

Association of fasting blood glucose to high-density lipoprotein cholesterol ratio with short-term outcomes in patients with acute coronary syndrome

“…Several novel biomarkers have been reported in recent years, including microRNAs [ 17 ] and long non-coding ribonucleic acids [ 18 ]. However, measuring these biomarkers is expensive, time-consuming, and complicated.…”